Holen Sie sich die Stockscreener-App
2.70
1.82%
-0.05
Handel nachbörslich:
2.69
-0.01
-0.37%
Cytomx Therapeutics Inc Aktie (CTMX) Neueste Nachrichten
CytomX Therapeutics stock gains 6.52 percent on September 23 - AD HOC NEWS
CytomX Therapeutics Inc (6C1) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
CytomX at Morgan Stanley conference: late-line crc push gains focus - Investing.com India
CytomX Therapeutics, Inc. Share Price Live Today – NASDAQ:CTMX Stock Price, Chart, News, History - Upstox
CytomX Therapeutics, Inc. (CTMX) Presents at Wells Fargo 21st Annual Healthcare ConferenceSlideshow - Seeking Alpha
CytomX at cantor healthcare conference: pipeline gains, safety test ahead By Investing.com - Investing.com South Africa
CytomX at cantor healthcare conference: pipeline gains, safety test ahead - investing.com
CytomX at Wells Fargo conference: epcam bet and cash strength - Investing.com
CytomX at Wells Fargo conference: epcam bet and cash strength By Investing.com - Investing.com UK
CTMXCytomX Therapeutics Inc Revenue Breakdown - Finviz
CytomX Therapeutics to Present at Upcoming September Investor Conferences - Stock Titan
CytomX Therapeutics Inc. (CTMX) Peer Comparison – Compare with Others - Value Research
FDA grants fast track status to CytomX’s colorectal cancer drug By Investing.com - Investing.com Canada
FDA grants fast track status to CytomX’s colorectal cancer drug - Investing.com India
CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC) - Yahoo Finance
CytomX (CTMX) Stock: Ends Up by 1.37% at $3.33 for the Current Session; the Price Remains Bounded by the Supplied Support and Resistance in the Current UpdateVanna Flow - siam.in
CytomX Therapeutics (NASDAQ:CTMX) Downgraded to "Hold" Rating by Zacks Research - MarketBeat
CytomX Therapeutics (CTMX) Climbs 2.68% to $3.45, Trades Within Key Support-Resistance RangeHidden Order - vinanet.vn
CytomX Therapeutics (NASDAQ:CTMX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Point72’s 3.6% CytomX Therapeutics (CTMX) stake detailed in amended filing - Stock Titan
Kynam Capital reports 9.96% CytomX Therapeutics (CTMX) ownership in Schedule 13G/A - Stock Titan
CytomX Therapeutics, Inc.: Target Price Consensus and Analysts Recommendations | CTMX | US23284F1057 - marketscreener.com
CTMX Maintained by JP Morgan -- Price Target Lowered to $11.00 - GuruFocus
CytomX Therapeutics (NASDAQ:CTMX) Given New $11.00 Price Target at JPMorgan Chase & Co. - MarketBeat
CytomX Therapeutics Is Maintained at Overweight by JP Morgan - Moomoo
Bank of America Corp DE Has $47.95 Million Position in CytomX Therapeutics, Inc. $CTMX - MarketBeat
MSN Money - MSN
CytomX Therapeutics: Promising Varseta-M With Comfortable Runway (NASDAQ:CTMX) - Seeking Alpha
CTMX Maintained by Guggenheim -- Price Target Lowered to $14.00 - GuruFocus
Guggenheim cuts CytomX stock price target to $14 on model update - Investing.com South Africa
CytomX Therapeutics, Inc. $CTMX Shares Purchased by Dimensional Fund Advisors LP - MarketBeat
Q2 2026 CytomX Therapeutics Inc Earnings Call Transcript - GuruFocus
Q4 2025 CytomX Therapeutics Inc Earnings Call Transcript - GuruFocus
Analysts Offer Insights on Healthcare Companies: CytomX Therapeutics (CTMX), Cytokinetics (CYTK) and Scholar Rock Holding (SRRK) - The Globe and Mail
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Rating of "Buy" by Brokerages - MarketBeat
CytomX Therapeutics (NASDAQ:CTMX) Announces Earnings Results - MarketBeat
CytomX Therapeutics, Inc. Stock 12‑Month Price Target Cut to $12.38, Implies 267% Upside - TradingView
State Street Corporation (CTMX) reports 5.4% beneficial stake in CytomX Therapeutics - Stock Titan
CytomX Therapeutics Inc (CTMX) (Q2 2026) Earnings Call Highlight - GuruFocus
CytomX Therapeutics Inc (CTMX) (Q2 2026) Earnings Call Highlights: Varetta M Advances Toward ... - Yahoo Finance
CytomX Therapeutics secures $37M from Regeneron amid Q2 revenue miss - scanx.trade
CytomX Q2 2026 Earnings: Revenue Falls as R&D Spending Rises - TradingKey
CytomX Therapeutics Q2 Earnings Call Highlights - marketbeat.com
CTMX Looks 1148.1% Overvalued on GF Value™ - GuruFocus
Earnings call transcript: CytomX misses Q2 2026 estimates as cash runway extends - Investing.com
CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Is CytomX Therapeutics Inc (CTMX) Facing Financial Headwinds Aft - GuruFocus
CytomX Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update - The Manila Times
CytomX enrolls 113 patients; next colorectal cancer trial planned - Stock Titan
CytomX Therapeutics posts Q2 2026 results — $1.4M revenue, $25.2M operating expense, $330.3M cash - TradingView
CytomX Therapeutics 2Q 2026: Revenue $1.42M, EPS $(0.09) — 10-Q Summary - TradingView
CytomX Therapeutics, Inc. (CTMX) awards 450,000 options and 100,000 RSUs to CLO - Stock Titan
CytomX Therapeutics, Inc. (CTMX) Chief Legal Officer files Form 3 insider report - Stock Titan
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):